Searched for
JUBILANT GENERICS
These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...- Jubilant Pharmova's US arm prepays Rs 626 crore term loanJubilant Pharmova's US subsidiary secured a $75 million term loan, as of March 31, 2024, the company's gross debt stood at Rs. 3,414 crore ...
- Manufacturing issues led drug makers Glenmark, Sun Pharma, Dr Reddy's to recall products in USAs per the US health regulator, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may caus...
- Drug makers Granules India, Jubilant Cadista recall products in US marketSalisbury-based Jubilant Cadista Pharmaceuticals Inc is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of Noida-based Ju...
- Lupin, Sun Pharma, Jubilant Cadista recall drugs in US marketAccording to the USFDA, the company is recalling the affected lot for being "Superpotent". The affected lot has been manufactured at Lupin'...
- Saptagir Laboratories signs deal with Jubilant Generics to manufacture 'Remdesivir'Remdesivir is an experimental antiviral drug developed by Gilead Sciences, Inc. as a course of treatment for Covid-19. Gilead entered into ...
- Jubilant Life Sciences arm launches Remdesivir injection in the Indian marketJubilant Generics will make the drug available to over 1,000 hospitals providing Covid-19 treatment in India through its distribution netwo...
- This pharma stock rallies 4% as firm gets DCGI nod for Covid drug, RJ ups stakeThe company will distribute the drug in the Indian market through its network and it will be available by the first week of August 2020, th...
- Jubilant Life Sciences says no traces of Covid-19 in raw material imported to its Nanjangud facilityThe press statement was issued in the backdrop of 49 cases employees of the pharma facility Jubilant Life Sciences in Nanjangud and their p...
- Jubilant Life reports Q3 net profit at Rs 117 croreJubilant Life Sciences reported a net profit of Rs 116.93 crore for the third quarter ended December 31.
- Jubilant Life gets USFDA nod for hypertension, allergies drugsJubilant Life Sciences had a total of 781 filings for formulations of which 333 have been approved in various regions globally as on Decemb...
- Jubilant Life Sciences shares soar nearly 12 per centJubilant Life's stock soared 10.36 per cent to settle at Rs 159.85 on the BSE. In intra-day session, it advanced by 12.77 per cent to Rs 16...
- Jubilant gets USFDA nod for generic anti-hypertensive tabletsThe drug firm has received final approval from the US health regulator for Valsartan tablets and plans to launch the product immediately.
- Jubilant Life Sciences shares climb nearly 4 per centShares of Jubilant Life surged nearly 4% after IT received final approvals from USFDA for sale of generic anti-hypertensive Valsartan table...
- Jubilant Life Sciences gets FDA nod for Mycophenolate Mofetil & RizatriptanThe approvals are for Mycophenolate Mofetil in the strengths of 250 mg capsules and 500 mg tablets and Rizatriptan tablets in strengths of ...
- Jubilant acquires all outstanding shares of Cadista HoldingsJubilant Generics Inc had commenced the open offer to acquire all outstanding shares of the US-based Cadista Holdings Inc in November.
- Jubilant Life Sciences up 6%, hits fresh 52-week high on Rs 860 crore funding from IFCCompany's subsidiary, Jubilant Pharma will receive $147.5 mn funding from IFC to strengthen its generic drug manufacturing facilities.
- Jubilant Life Sciences gets USFDA nod for generic drugs"We expect to launch this product post patent expiry in 2015. The total market size for Namenda as per IMS is $1.85 billion per annum," the...
- Jubilant receives USFDA approval for two generic drugsJubilant Life Sciences Ltd today said it has received approval from the USFDA to market generic versions of GlaxoSmithKline's anti-depressa...
- Jubilant Life's four medicines get USFDA approvalJubilant Life Sciences said it has received approvals from the US health regulator for 4 products that target CNS and CVS therapeutic areas.
Load More
